Overview

Cancer is a formidable disease which disorganises the body in multiple ways; however, a less studied yet serious complication is thrombophlebitis, which is the production of painful blood clots via inflammation. Cancer patients, unfortunately, possess an elevated risk of blood clots, which is known as the hypercoagulable state. The interplay between the coagulation system and cancer can threaten the patient's comfort and also their survival. Understanding the mechanisms of how cancer can trigger the cascade reaction of clots is vital, as late diagnosis and poor intervention can lead to fatal complications such as pulmonary embolism (PE) and deep vein thrombosis (DVT).¹ The following article will explore the dynamic relationship between thrombophlebitis and cancer, examining the biological mechanisms, symptoms, diagnostic techniques, and treatment strategies. Whether you are a caregiver or a health care professional, or just seeking more knowledge, gaining insights into this disease is important for overall awareness and patient care.

Understanding the biological mechanisms between cancer and hypercoagulability

Cancer patients possess a significantly increased risk of blood clot formation via a condition known as cancer-associated hypercoagulability. The homeostatic disruption between clot formation and breakdown makes the blood more prone to clotting.² Multiple factors can trigger this state:

• Interaction of tumour cells with coagulation: Tumour cells can release procoagulant molecules such as cancer procoagulant and tissue factor, triggering a cascade of reactions that lead to a higher risk of clot formation
• Microparticles: Tumour cells contain multiple microparticles, which are tiny vesicles holding procoagulant molecules which can induce platelet formation and accelerate thrombosis
• Chronic inflammation: Systemic inflammation can damage the endothelium of blood vessels, making them susceptible to clotting. Furthermore, in combination with these proinflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) can trigger clot formation³

Specific cancers can lead to a higher risk of thrombophlebitis, including:

Lung cancer

A combination of tumour-associated tissue damage, chronic inflammation and disturbed circulation can produce an increased chance of venous thromboembolism (VTE). Certain treatment methods, such as chemotherapy, can increase the risk. Deep vein thrombosis can be life-threatening if misdiagnosed.

Gastrointestinal cancers

 These cancers affecting the stomach, intestines and liver are significantly related to portal vein thrombosis (PVT). This is a blood clot which blocks the flow in the portal vein, posing a risk of liver failure and ascites. The high concentration of pro-inflammatory cytokines can invade blood vessels to induce blood clot formation.⁴ 

Pancreatic cancer

This particular malignancy is known for its exceptionally elevated thrombosis potential. Studies have shown that a quarter of all pancreatic cancer patients will get a clot at some point. This is due to a significant release of tissue factor (TF), which initiates the coagulation cascade, leading to a higher risk of venous thromboembolism (VTE) and fatal complications.⁵ 

Awareness of the signs, symptoms, and diagnostic methods

The early detection of thrombophlebitis is difficult but still crucial. The symptoms can easily be mistaken for more minor conditions, such as skin irritation or muscle strains. There are key signs of patient experiences to be mindful of, including:

• Persistent tenderness and pain along the veins
• Localised redness and warmth
• And swelling in the legs.
• Veins which are firm to the touch

There are two types of thrombophlebitis, each with distinct risks. Superficial thrombophlebitis is localised to the superficial veins near the surface. This is considered milder and can be managed promptly as it responds well to treatment. However, the more serious type is deep vein thrombosis (DVT), which occurs in deeper and larger veins primarily within the legs.⁶ If not detected, deep vein thrombosis can further lead to a pulmonary embolism, a serious complication where a blood clot travels to the lungs, stopping blood flow.

Diagnosis of thrombophlebitis is primarily done through blood work and imaging tests. The most reliable and common method is known as a Doppler ultrasound, which utilises sound waves to detect blood clots and measure blood flow. Some patients require a D-dimer blood test, which can detect any proteins involved in clot formation. Increased levels may suggest a clot, which needs further investigation.⁷ MRI and CT venography can produce high-resolution images of clots within deeper veins. Detecting symptoms early and using efficient diagnostic methods can provide effective treatment and prevent any serious complications.

Treatment of thrombophlebitis: Balancing safety and effectiveness

Treatment of thrombophlebitis in cancer patients is a sensitive yet balancing act. Preventing clots from growing further alongside avoiding excessive bleeding, which is already a posed risk due to certain cancer treatments. The primary line of treatment is anticoagulant medication, which uses blood thinners to prevent clots from growing and to stop the formation of new ones. These treatments include:

• Oral anticoagulants: These are very common across healthcare settings as they are easy to use and are very convenient; however, these can pose an increased risk of bleeding in cancer patients
• Warfarin: Not as commonly used for cancer patients as it can interact with chemotherapy and also requires more frequent monitoring, reducing its practicality
• Low-molecular-weight heparin (LMWH): This is the go-to option for thrombosis in cancer patients as it poses a low risk of bleeding whilst also providing effective clot prevention⁸

In combination with medication, supportive care plays a significant role in increasing comfort and managing symptoms:

• Pain relief: Paracetamol and non-steroidal anti-inflammatory drugs can reduce discomfort caused by inflamed veins. Stronger opiates such as tramadol and morphine may be recommended by healthcare professionals for extreme pain
• Compression stockings: These aid in reducing swelling in the lower extremities by boosting circulation to prevent the formation of further clots. These are convenient as they are readily available over the counter (OTC)

In clinical cases, combining coagulation therapy with supportive methods can significantly manage thrombophlebitis in cancer patients, reduce further complications and increase the quality of life.⁹

Long-Term impact and prognosis

Unfortunately, thrombophlebitis in cancer patients is very complicated and doesn't finish with treatment; there's a lifelong risk of clots recurring, which requires long-term anticoagulation therapy.¹⁰ Although this can be disheartening, effective management reduces the chances of serious complications such as DVT and PE. The impact of thrombosis extends beyond clotting; it can significantly affect cancer patient outcomes. Blood clots can disturb blood flow to tumours, which can make chemotherapy less effective and reduce survival chances.¹¹

In the future, advances in cancer-related thrombosis can produce overall better outcomes. Scientists are en route to developing anticoagulants which are safer and have fewer side effects, aiming to heal the homeostatic disruption between clot formation and breakdown.¹² Researchers are thoroughly investigating biomarkers to provide insight into which cancer patients are at higher risk of thrombosis, which paves the way for time-efficient detection and treatment. These promising innovations make the future treatment of thrombophlebitis hopeful and personalised.

Summary

Thrombophlebitis in cancer patients is a serious yet effectively manageable condition. 

This can be hidden beneath the surface but can lead to serious complications if not treated promptly. Cancer can lead to a hypercoagulable state and can increase the risk of serious clots, indicating that early detection and intervention are critical. Keeping an eye out for unexplained subtle symptoms such as warmth, swelling and tenderness can aid in providing a faster diagnosis and reduce the chances of serious complications such as pulmonary embolism, which can be fatal. Anticoagulation therapy has provided significant hope by increasing the overall outlook for patients. The gold standard for cancer-related clots is low-weight molecular-weight heparin (LMWH), whilst newer oral anticoagulants provide more reliable convenience and effectiveness. In combination with medication, compression stockings and pain management strategies play a crucial role in decreasing discomfort. Beyond the stakes of treatment, monitoring, and prevention are vital. Long-term therapy is desirable to reduce the risk of recurrence. Research into new biomarkers and unique anticoagulation strategies can provide hope for more personalised treatments. For doctors, patients and caregivers, understanding the significant threat of thrombophlebitis in cancer patients is vital. Keeping up to date with information can improve patient outcomes, prevent complications and increase the quality of life.